Simultaneously, a high level of expression of epithelial growth factor receptor (EGFR) in IBC was associated with a poor prognosis [21], and lapatinib followed by surgical resection or chemotherapy could increase the clinical response rate in HER2+ IBC patients [22]. This evidence concerns the gene EGFR and inflammatory breast carcinoma.